Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10019447HBVENSG00000159403.18protein_codingC1RNoNo715P00736
TVIS10061391HBVENSG00000159403.18protein_codingC1RNoNo715P00736
TVIS10061390HBVENSG00000159403.18protein_codingC1RNoNo715P00736
TVIS10061392HBVENSG00000159403.18protein_codingC1RNoNo715P00736
TVIS10061387HBVENSG00000159403.18protein_codingC1RNoNo715P00736
TVIS10061393HBVENSG00000159403.18protein_codingC1RNoNo715P00736
TVIS10061388HBVENSG00000159403.18protein_codingC1RNoNo715P00736
TVIS10061389HBVENSG00000159403.18protein_codingC1RNoNo715P00736
TCGA Plot Options
Drug Information
GeneC1R
DrugBank IDDB00110
Drug NamePalivizumab
Target IDBE0002093
UniProt IDP00736
Regulation Type
PubMed IDs24711420
CitationsHiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L: Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5992-7. doi: 10.1073/pnas.1402458111. Epub 2014 Apr 7.
GroupsApproved; Investigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKBPA164748781
ChEMBLCHEMBL1201586